Filter by patients with: All

What is MS Phase 3 Study Laquinimod?

Category: Others

false

See also: Clinical Trial

NCT00509145 is a completed randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis. Other study names are MS-LAQ-301, EUDRACT 2007-003226-19.

See patients taking MS Phase 3 Study Laquinimod

See 1 patient that have used MS Phase 3 Study Laquinimod

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 0

Commonly reported side effects and conditions associated with MS Phase 3 Study Laquinimod

Side effect Patients Percentage
Back pain 1
Last updated:
There are no evaluations for MS Phase 3 Study Laquinimod.